申请人:The Boots Company Plc
公开号:US04659718A1
公开(公告)日:1987-04-21
Novel quinolones of formula I ##STR1## and pharmaceutically acceptable acid addition salts thereof in which the dotted line between positions 2 and 3 of the quinolone ring represents an optional bond, R is hydrogen, 1-methyl or 2-lower alkyl; R.sub.1 is lower alkyl; R.sub.2 is hydrogen, halo, lower alkyl, lower alkoxy, trifluoromethyl, cyano, difluoromethoxy, methylsulphinyl, phenylsulphinyl or the group --NR.sub.4 R.sub.5 or the N-oxide thereof wherein R.sub.4 and R.sub.5, which may be the same or different, are lower alkyl or, together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or morpholino radical; and R.sub.3 is hydrogen, fluoro, lower alkyl or lower alkoxy provided that, when R.sub.3 is lower alkoxy, R.sub.2 is other than lower alkoxy have utility as antihypertensive agents. Processes for preparing the quinolones and pharmaceutical compositions containing them are disclosed.
化学式I的新型喹诺酮及其药学可接受的酸盐,其中喹诺环的2和3位置之间的虚线代表可选键,R为氢,1-甲基或2-较低烷基;R.sub.1为较低烷基;R.sub.2为氢,卤素,较低烷基,较低烷氧基,三氟甲基,氰基,二氟甲氧基,甲基砜基,苯基砜基或基团--NR.sub.4 R.sub.5或其N-氧化物,其中R.sub.4和R.sub.5可以相同也可以不同,为较低烷基或者与它们连接的氮原子形成吡咯烷基,哌啶基或吗啉基;R.sub.3为氢,氟,较低烷基或较低烷氧基,但当R.sub.3为较低烷氧基时,R.sub.2不是较低烷氧基,具有作为降压药的用途。公开了制备喹诺酮和含有它们的药物组合物的方法。